PE20221020A1 - Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1Info
- Publication number
- PE20221020A1 PE20221020A1 PE2021002218A PE2021002218A PE20221020A1 PE 20221020 A1 PE20221020 A1 PE 20221020A1 PE 2021002218 A PE2021002218 A PE 2021002218A PE 2021002218 A PE2021002218 A PE 2021002218A PE 20221020 A1 PE20221020 A1 PE 20221020A1
- Authority
- PE
- Peru
- Prior art keywords
- modulator
- methyl
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- positive
- Prior art date
Links
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- SVTDEVFVOSMAQQ-UONOGXRCSA-N ClC1=NN(C2=CC=C(C(=C12)CC(=O)N1[C@H](C2=CC=CC(=C2C[C@@H]1CO)C(C)(C)O)C)Cl)C Chemical compound ClC1=NN(C2=CC=C(C(=C12)CC(=O)N1[C@H](C2=CC=CC(=C2C[C@@H]1CO)C(C)(C)O)C)Cl)C SVTDEVFVOSMAQQ-UONOGXRCSA-N 0.000 abstract 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 abstract 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 | ||
| PCT/EP2020/068183 WO2021001288A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221020A1 true PE20221020A1 (es) | 2022-06-16 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002218A PE20221020A1 (es) | 2019-07-01 | 2020-06-29 | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12643877B2 (enExample) |
| EP (1) | EP3993794A1 (enExample) |
| JP (1) | JP7510444B2 (enExample) |
| KR (1) | KR20220029686A (enExample) |
| CN (2) | CN117700395A (enExample) |
| AR (1) | AR119318A1 (enExample) |
| AU (1) | AU2020299953B2 (enExample) |
| BR (1) | BR112021022378A2 (enExample) |
| CA (1) | CA3139571A1 (enExample) |
| CL (1) | CL2021002946A1 (enExample) |
| CO (1) | CO2021018155A2 (enExample) |
| EC (1) | ECSP21093559A (enExample) |
| IL (2) | IL319939A (enExample) |
| MA (1) | MA56440A (enExample) |
| MX (2) | MX2021015873A (enExample) |
| MY (1) | MY210361A (enExample) |
| PE (1) | PE20221020A1 (enExample) |
| PH (1) | PH12021552825A1 (enExample) |
| SA (1) | SA521431279B1 (enExample) |
| SG (1) | SG11202112537YA (enExample) |
| TW (1) | TWI875776B (enExample) |
| WO (1) | WO2021001288A1 (enExample) |
| ZA (1) | ZA202109193B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| EP4200280B1 (en) | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| SI4263517T1 (sl) | 2020-12-18 | 2025-01-31 | UCB Biopharma SRL | Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1 |
| CN116685308A (zh) | 2020-12-18 | 2023-09-01 | Ucb生物制药有限责任公司 | 无定形固体分散体 |
| ES3004257T3 (en) | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| CN117337173A (zh) * | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
| WO2026022198A1 (en) | 2024-07-25 | 2026-01-29 | UCB Biopharma SRL | Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520217A (ja) * | 2007-03-01 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物 |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| EA035544B1 (ru) | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 PH PH1/2021/552825A patent/PH12021552825A1/en unknown
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 JP JP2021577411A patent/JP7510444B2/ja active Active
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 US US17/621,851 patent/US12643877B2/en active Active
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 MY MYPI2021006862A patent/MY210361A/en unknown
- 2020-06-29 MA MA056440A patent/MA56440A/fr unknown
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/pt unknown
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/zh active Pending
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/zh active Active
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/es unknown
- 2020-06-29 AU AU2020299953A patent/AU2020299953B2/en active Active
- 2020-06-29 IL IL319939A patent/IL319939A/en unknown
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/es unknown
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en not_active Ceased
- 2020-06-29 IL IL289314A patent/IL289314B2/en unknown
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/ko active Pending
- 2020-06-30 AR ARP200101853A patent/AR119318A1/es unknown
- 2020-06-30 TW TW109122035A patent/TWI875776B/zh active
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/es unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-16 MX MX2024015493A patent/MX2024015493A/es unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/es unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/es unknown
- 2021-12-30 SA SA521431279A patent/SA521431279B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191406A1 (es) | N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| MX2020000261A (es) | Nuevos compuestos. | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| PE20181010A1 (es) | Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos | |
| UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| UY31431A1 (es) | Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap) | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| CR20200481A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina di | |
| AR062471A1 (es) | SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU | |
| PE20091080A1 (es) | 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7 | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| PE20220373A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| ECSP11011415A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
| MA38697A1 (fr) | 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7 | |
| CL2009000896A1 (es) | Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades. | |
| PE20090877A1 (es) | 1,2,4-triazoles trisustituidos | |
| PE20240632A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1 | |
| PE20150708A1 (es) | Derivados de ariletinilo |